GT Medical Technologies Completes Final Close of Company’s Oversubscribed $53 Million Series D Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
TEMPE, Ariz., July 15, 2025 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced the company has completed the close of its oversubscribed $53 million Series D equity financing.
The final close of the Series D comprised an additional $16 million from new investors including FemHealth Ventures, Warren Point Capital, an undisclosed strategic investor, and increased commitments from all existing institutional investors. Earlier this year, GT Medical Technologies announced the completion of a $37 million first close of the Series D equity financing led by Evidity Health Capital, alongside new investor Accelmed Partners and existing investors MVM Partners, Gilde Healthcare, and Medtech Venture Partners.
